In a 2-year trial, acute pancreatitis was reported in 8 semaglutide-treated patients (0.27 cases per 100 patient-years) and 10 placebo-treated patients (0.33 cases per 100 patient-years), both on a background of standard of care.1 In trials of patients receiving oral semaglutide, pancreatitis was reported as a serious adverse event in 6 patients (0.1 events per 100 patient-years) receiving semaglutide versus 1 in comparator-treated patients (less than 0.1 events per 100 patient-years)
Its about more than just a single medication
According to UCLA Health, semaglutide was the first drug approved since 2014 specifically for chronic weight management in the majority of American adults who are classified as overweight or obese, yet insurance treatment of that weight-loss indication still lags well behind how insurers treat the diabetes indication for the same molecule
Accidental intramuscular deposition during intended SubQ administration is indicated by a distinct resistance or pop sensation as the needle penetrates muscle fascia, followed by disproportionate post-injection soreness lasting 48+ hours
The full-time faculty of more than 3,300 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments
Unfortunately, some users have experienced serious, debilitating, and life-changing side effects or complications from these drugs